EUVIMEDEUVIMED entdecken
Crossref

Transdermal Dextroamphetamine (Xelstrym) for ADHD

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Methylphenidate.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved a dextroamphetamine transdermal patch (Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US. A methylphenidate transdermal patch (Daytrana, and generics) has been available for years for treatment of ADHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateHumansAdministration, CutaneousDextroamphetamine

Stichwörter der Autor:innen

ADHDDaytranaXelstrymadverse effectsdextroamphetaminedosagedrug interactionsefficacylactationmethylphenidatepregnancysafety

Substanzen

Central Nervous System StimulantsMethylphenidateDextroamphetamine

Zitieren

APA

(2023). Transdermal Dextroamphetamine (Xelstrym) for ADHD. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669d

Vancouver

Transdermal Dextroamphetamine (Xelstrym) for ADHD. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669d

BibTeX
@article{euvimed2023,
  title = {Transdermal Dextroamphetamine (Xelstrym) for ADHD},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669d}
}
Kostenlos starten →